s and uncertainties, many of which are difficult to predict and include statements regarding the use of zinc as a potential treatment for cognitive deficits in Alzheimer's patients and our intent to further commercialize development of reaZin as a prescription medical food. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, our failure to successfully commercialize reaZin for the treatment of Alzheimer's disease, the failure of reaZin to be accepted as a treatment for Alzheimer's disease, failure of future clinical trials studying reaZin to have favorable results, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
(1) O'Brien, P.C., "Procedures for Comparing Samples with Multiple Endpoints," Biometrics, 40, 1079-1087, 1984.
(2) Squitti, R., Pasqualetti, P., Dal Forno, G., et al., "Excess of serum copper not related to ceruloplasmin in Alzheimer disease," Neurology, vol. 64, no. 6, pp 1040-1046, 2005.
(3) Squitti, R., Barbati, G., Rossi, L., et al., "Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau," Neurology, vol. 67, no. 1, pp 76-82, 2006.
(4) Squitti, R., Bressi, P., Pasqualetti, R, et al., "Longitudinal prognostic value of serum "free" copper in patients with Alzheimer's disease," Neurol
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Adeona Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial2
. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions3
. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome4
. Visual Healthcare to Support Chinese Clinical Trials5
. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy6
. Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant7
. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®8
. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V7109
. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema10
. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance11
. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System